303. アッシャー症候群
[臨床試験数:6,薬物数:11(DrugBank:0),標的遺伝子数:0,標的パスウェイ数:0]

Searched query = "Usher syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-002574-31-FR
(EUCTR)
25/10/201315/05/2014Study of SAR421869 in Patients With Retinitis Pigmentosa associated with Usher Syndrome Type 1BA Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR421869, Administered to Patients with Retinitis Pigmentosa Associated with Usher Syndrome Type 1B Retinitis Pigmentosa, associated with Ushers Syndrome Type 1B.
MedDRA version: 20.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Classification code 10063396;Term: Usher's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
sanofi-aventis recherche & développementNULLNot Recruiting Female: yes
Male: yes
27Phase 1;Phase 2United States;France
2NCT02065011
(ClinicalTrials.gov)
September 12, 201314/2/2014A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1BAn Open-label Study to Determine the Long-term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1BUsher's SyndromeDrug: Blood draw for the laboratory assessmentSanofiNULLActive, not recruiting18 YearsN/AAll9Phase 1;Phase 2United States;France
3NCT01505062
(ClinicalTrials.gov)
March 26, 20124/1/2012Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1BA Phase I/IIA Dose Escalation Safety Study of Subretinally Injected SAR421869, Administered to Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1BUsher Syndrome;Retinitis PigmentosaDrug: SAR421869SanofiNULLTerminated6 YearsN/AAll9Phase 1;Phase 2United States;France